Petrukhin A S, Voronkova K V, Pylaeva O A
Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(6 Pt 2):65-71.
The new antiepileptic drug (AED) lacosamide (vimpat, "UCB Pharma") with a new mechanism of action was registered in Russia in 2010. The drug should be used as add-on treatment in patients over 16 years and older with non-controlled focal seizures with- or without secondary localization. The authors review the data of literature and the results of trials on efficacy and safety of lacosamide for peroral and intravenous introduction. Randomized clinical trials of the peroral form of this drug provide evidence that lacosamide is a prospective preparation for complex treatment of drug-resistant epilepsy in the view of its safety and tolerability. The availability of the infusion form is advantageous compared to other AED making it possible to continue treatment in cases when the peroral intake of AED is temporary impossible.
新型抗癫痫药物（AED）拉科酰胺（万适宁，“优时比制药公司”）具有全新作用机制，于2010年在俄罗斯注册。该药物应用于16岁及以上患有局灶性癫痫发作且控制不佳（无论是否伴有继发性定位）的患者，作为附加治疗。作者回顾了有关拉科酰胺口服和静脉注射的疗效与安全性的文献数据及试验结果。该药物口服剂型的随机临床试验表明，鉴于其安全性和耐受性，拉科酰胺是耐药性癫痫综合治疗的一种有前景的制剂。与其他抗癫痫药物相比，拉科酰胺注射剂型的可用性具有优势，使得在暂时无法口服抗癫痫药物的情况下仍可继续治疗。
